• English
    • français
  • Help
  •  | 
  • Contact
  •  | 
  • About
  •  | 
  • Login
  • HAL portal
  •  | 
  • Pages Pro
  • EN
  •  / 
  • FR
View Item 
  •   LillOA Home
  • Liste des unités
  • Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
  • View Item
  •   LillOA Home
  • Liste des unités
  • Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Scoring System Based on Post-Transplant ...
  • BibTeX
  • CSV
  • Excel
  • RIS

Document type :
Article dans une revue scientifique
DOI :
10.1016/j.retram.2018.08.003
PMID :
30206045
Permalink :
http://hdl.handle.net/20.500.12210/4497
Title :
Scoring System Based on Post-Transplant Complications in Patients after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Study from the SFGM-TC.
Author(s) :
Caulier, Alexis [Auteur]
Drumez, Elodie [Auteur]
Gauthier, Jordan [Auteur]
Robin, Marie [Auteur]
Blaise, Didier [Auteur]
Beguin, Yves [Auteur]
Michallet, Mauricette [Auteur]
Chevallier, Patrice [Auteur]
Bay, Jacques-Olivier [Auteur]
Vigouroux, Stephane [Auteur]
Desbrosses, Yohan [Auteur]
Cornillon, Jerome [Auteur]
Nguyen, Stephanie [Auteur]
Dauriac, Charles [Auteur]
Peffault De Latour, Regis [Auteur]
Lioure, Bruno [Auteur]
Rohrlich, Pierre-Simon [Auteur]
Carre, Martin [Auteur]
Bourhis, Jean-Henri [Auteur]
Huynh, Anne [Auteur]
Suarez, Felipe [Auteur]
Garnier, Federico [Auteur]
Duhamel, Alain [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Yakoub Agha, Ibrahim [Auteur] refId
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Journal title :
Current research in translational medicine
Abbreviated title :
Curr. Res. Transl. Med.
Publication date :
2018-09-08
ISSN :
2452-3186
2452-3186
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
PURPOSE: We developed a prognostic scoring system to evaluate the prognosis of myelodysplastic syndrome (MDS) patients surviving more than 100 days allogeneic hematopoietic cell transplantation after (allo-HCT). PATIENTS ...
Show more >
PURPOSE: We developed a prognostic scoring system to evaluate the prognosis of myelodysplastic syndrome (MDS) patients surviving more than 100 days allogeneic hematopoietic cell transplantation after (allo-HCT). PATIENTS AND METHODS: We performed a landmark analysis on a derivation cohort of 393 cases to identify prognostic factors for 3-year overall survival. Potential predictor variables included demographic and clinical data, transplantation modalities and early post-transplant complications. The scoring system was tested against a validation cohort which included 391 patients. RESULTS: Complications occurring before day 100 such as relapse [HR = 6.7; 95%CI, 4.5-10.0] (4 points), lack of platelet recovery [HR, 3.6; 95%CI, 2.2-5.8] (2 points), grade-II acute GVHD [HR = 1.7; 95%CI, 1.2-2.5] (1 point) and grade-III/IV [HR = 2.6; 95%CI, 1.8 -3.8] (2 points) were the only independent predictors of 3-year OS. The 3-year OS associated with low (0), intermediate (1-3) and high (>/=4) risk scores was respectively 70%, 46% and 6%. The model performed consistently in both cohorts, with good calibration. CONCLUSION: This post-transplant scoring system is a powerful predictor of outcome after allo-HCT for MDS, and can provide useful guidance for clinicians. Additional studies are required to evaluate this scoring system for other hematologic malignancies.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Inserm
Université de Lille
CHU Lille
Collections :
  • Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
  • METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Research team(s) :
Immunity, inflammation and fibrsis in auto and allo-reactivity
Submission date :
2019-03-01T14:07:58Z
Université de Lille

Mentions légales
Université de Lille © 2017